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Atherosclerosis is accelerated in rheumatoid arthritis (RA) and psoriatic arthritis (PsA). We investigated a possible association
of oxidized low-density lipoproteins (ox-LDLs), nitric oxide (NO), 3-nitrotyrosine, vitamin A, vitamin E, and β-carotene serum
levels with subclinical atherosclerosis in RA and PsA. By the use of ELISA, we observed higher ox-LDL levels in patients with
intima-media thickness (IMT) > 1 than in patients with IMT ≤ 1 and a negative correlation between NO levels and IMT values.
By the use of high-performance liquid chromatography, we determined higher levels of vitamin A in patients with PsA and IMT
≤ 1 than in controls and lower levels of β-carotene in patients with RA and PsA than in controls. β-carotene concentrations were
negatively correlated to the duration of disease in RA. Our study conﬁrms that ox-LDLs and NO may be markers of accelerated
atherosclerosis in RA and PsA whereas vitamins seem to be associated only to the presence of the autoimmune disorders.
1.Introduction
Many studies have reported an excess of cardiovascular
morbidity and mortality among patients with chronic
inﬂammatory diseases of the musculoskeletal system such as
rheumatoid arthritis RA [1]. In patients with active RA, the
majority of cardiovascular deaths are caused by accelerated
atherosclerosis [2–4] probably due to the chronic activation
of inﬂammatory mechanisms. As previously reported in
patients with (RA) [5], recent data have demonstrated the
presenceofendothelialdysfunctioninpatientswithpsoriatic
arthritis (PsA) [6, 7]. The occurrence of cardiovascular
disease in this pathology might be directly linked to the
activation of inﬂammatory mediators in the skin and joints
[8].
As RA and probably PsA predispose to atherosclerosis, an
important issue is how to prevent this outcome. In the last
decade,greatattentionhasbeenfocusedontheidentiﬁcation
of risk factors predisposing to atherosclerotic disease [9, 10]
and on the associations of acute systemic inﬂammation
markers with atherosclerosis [11, 12]. It is well known that
theinﬂammatoryoverload,accompaniedtothecombination
of an excessive production of reactive oxygen species and
an impaired antioxidant defence capacity [13, 14], leads to
oxidative stress in patients with rheumatic diseases and this
may play an important role in driving the rheumatic disease
as well as cardiovascular complications. However, the precise
roleofoxidative stressintheprogressionofthesepathologies
remains largely elusive. Defences against oxidative stress rely
closely on vitamins, which are potent nonenzymatic antiox-
idants. Previous observational studies have suggested that
antioxidants may protect against the development of RA, but
the results for individual antioxidants are conﬂicting [15]. In
addition, gene interactions suggest a potential contribution2 Mediators of Inﬂammation
of inducible and endothelial nitric oxide synthase (NOS2A
and NOS3) gene polymorphisms to cardiovascular event
susceptibility in patients with RA [16]. The present study
was undertaken to conﬁrm our preliminary ﬁndings on ox-
LDLs and NO as indicators of atherosclerosis development
in patients with RA and PsA [17], as well as to investigate
the possible role of serum vitamins as biomarkers of
cardiovascular risk in patients with autoimmune disorders.
For this purpose, we determined serum levels of ox-LDLs,
NO,3-nitrotyrosine,vitaminA,vitaminE,andβ-carotenein
patients with RA and PsA divided into two groups according
to the presence or not of atherosclerotic disease determined
by Echo-colour Doppler ultrasonography. As controls, we
used healthy subjects free of atherosclerotic disease. We
also investigated whether serum biomarkers were related to
traditional risk factors for atherosclerosis or to the duration
of the autoimmune disease.
2.MaterialsandMethods
2.1. Study Population. We enrolled 49 consecutive patients
(24withRAfulﬁllingtheAmericanCollegeofRheumatology
criteria and 25 with PsA fulﬁlling the Classiﬁcation Criteria
for Psoriatic Arthritis) [18, 19] and 13 sex- and age-
matchedhealthysubjects. Exclusion criteria forpatients were
(i) recent infections (<1 month), (ii) other autoimmune
diseases, (iii) malignancy, (iv) inﬂammatory diseases before
enrollment, (v) proven coronary artery disease, and (vi)
diabetes mellitus or uncontrolled hypertension. All patients
were taking disease modifying antirheumatic drugs at the
time of enrolment. The inclusion criteria for healthy subjects
were no history of myocardial infarction, coronary bypass,
coronary angiography with angioplasty or stenting or both,
absence of inducible coronary ischemia, demonstrated by an
electrocardiogram and a color-doppler echocardiogram per-
formed at rest and during exercise, no history of cerebrovas-
cular accident, or peripheral vascular disease, and absence
of recent infections or inﬂammatory diseases. Furthermore,
none of healthy subjects had ultrasonographically evident
carotid or femoral atherosclerotic disease. All hematological
variables, including risk factors for atherosclerosis, were in
the range of “normal” values. Both controls and patients
who followed a standard Mediterranean diet did not take
antioxidants, integrators, and/or vitamins and conducted a
modest level of daily activity. Serum samples were obtained
from patients and controls and stored at −80◦C until
use. The study protocol was approved by the local Ethics
Committee and informed consent was obtained from all
participants.
2.2. Intima-Media Thickness of the Common Carotid Arteries.
The presence of atherosclerosis in patients and healthy
subjects was evaluated by measurement of intima-media
thickness (IMT) of the common carotid arteries. A recent
meta-analysis disclosed that patients with RA have abnor-
mally increased values of carotid IMT when compared with
matched controls [20]. It was also the case in patients with
PsA, even in those without classic cardiovascular risk factors
[21]. Since a recent study also disclosed that a value of
carotid greater than 0.90mm predicts the development of
cardiovascular events in patients with RA [22] and a carotid
IMT value greater than 0.90mm was also considered index
of subclinical atherosclerosis [23], we stratiﬁed individuals
into twogroupsaccordingtocarotidIMTvaluesgreaterthan
1.0mm or equal to or lower than 1.0mm. An IMT value > 1
was considered index of subclinical atherosclerosis.
High resolution B-mode Ultrasonography Echo-colour
Doppler Images were acquired on an ultrasound system
equipped with a 7.5MHz frequency linear-array transducer.
2.3. Serum Levels of ox-LDLs, NO and 3-Nitrotyrosine. ox-
LDLs, NO, and 3-nitrotyrosine concentrations in serum sam
ples from patients and healthy subjects were quantiﬁed
with commercially available ELISA kits (Oxidized LDL
Competitive ELISA, Mercodia, Uppsala, Sweden for ox-
LDL; OxiSelect Nitrotyrosine ELISA Kit, Cell Biolabs, San
Diego, CA, USA; Nitrate/Nitrite Colorimetric Assay Kit,
Cayman, Lausen Switzerland for NO), as recommended by
the manufacturer. The detection limits of the assays were
≤0.3U/L for ox-LDLs, <2.5μM for NO, and 1.95nM for 3-
nitrotyrosine.
2.4. Serum Levels of Vitamin A, Vitamin E, and β-Caro-
tene. Serum levels of vitamin A, E, and β-carotene were
determined by a high-performance liquid chromatography
(HPLC) method [24]. Brieﬂy, serum was deproteinised with
ethanol containing internal standard (α-tocopherol acetate)
and extraction of the analytes of interest was performed
using hexane. Analysis was carried out using reversed-phase
HPLC (kromasil 5μm, Phenomenex, Macclesﬁeld, UK) and
dual wavelength monitoring (S200, Perkin Elmer Instru-
ments, CT, USA). A methanol-n-hexane mixture (85:15)
w a su s e da se l u e n ta n dr u na t1 . 0 m Lm i n −1ﬂow rate and
25◦C[ 25].
2.5. Statistical Analysis. Data are expressed as medians
and interquartile ranges. Mann-Whitney nonparametric
test was used to investigate the signiﬁcance of unpaired
continuous data. Pearson’s chi-squared test or Fisher’s exact
test, when necessary, was used to evaluate the diﬀerences in
discrete baseline characteristics between groups of patients.
Correlations were explored by Spearman rank correlation
coeﬃcient. P values less than 0.05 were considered statisti-
cally signiﬁcant.
All the statistical procedures were performed by STATA
8.1 statistical package.
3. Results
3.1. Baseline and Clinical Characteristics of Patients. The
main demographic characteristics of the patients enrolled
are listed in the Table 1, where they are divided into two
groups according to IMT values. No signiﬁcant diﬀerences in
the distribution of baseline and clinical characteristics were
observed between patients with IMT > 1 and those with IMT
≤ 1.Mediators of Inﬂammation 3
Table 1:Baselinecharacteristicsofthe24patientswithrheumatoidarthritis(RA)andthe25withpsoriaticarthritis(PsA)dividedaccording
to intima-media thickness (IMT) values obtained by Echo-colour Doppler images.
Patients with RA Patients with PsA
IMT > 1I M T ≤ 1 Pc IMT > 1 IMT ≤ 1 Pc
N 61 8 1 1 1 4
Age (years), median (range) 54
(48–65)
55.5
(22–66) 0.424 48
(35–62)
52
(35–69) 0.369
Male/female (n) 1/5 2/16 1.0 7/4 10/4 1.0
Duration of the disease (years),
median (range)
6
(1–25)
3
(0.5–16) 0.149 4
(0.4–10)
9.5
(1–24) 0.073
Smokinga, n (%) 3 (50) 5 (28) 0.297 3 (27) 4 (28) 1.0
Hypertensionb, n (%) 2 (33) 2 (11) 0.194 2 (18) 0 (0) 0.183
Total cholesterol (mg/dL), median
(range)
159.5
(135–165)
155
(83–216) 0.774 170
(125–208)
179
(110–204) 0.756
HDL cholesterol (mg/dL), median
(range)
34
(26–48)
43
(14–78) 0.454 31
(18–54)
33
(17–58) 0.634
Triglycerides (mg/dL), median
(range)
85.5
(76–182)
79
(36–258) 0.526 103
(70–160)
98
(43–177) 0.382
ESR (mm/h) median (range) 16
(11–36)
21
(6–84) 0.449 15
(5–50)
7
(2–40) 0.088
CRP (mg/L), median (range) 5.5
(1.1−20)
2.5
(0–60) 0.716 1.35
(0–18)
2.13
(0–8.8) 0.396
Uricemia (mg/dL), median (range) 4.4
(2.9–6.2)
3.25
(2.1–8.0) 0.206 4.98
(2.9–8.7)
4.84
(2.3–11.2) 0.8
aSmoking is deﬁned as current smokers;
bHypertension is deﬁned as systolic blood pressure ≥140mmHg, diastolic blood pressure ≥90mm Hg, or need for hypertensive medication;
cPearson’s chi-squared test or Fisher exact test for discrete variables and Wilcoxon test for continuous variables to evaluate the presence of statistically
signiﬁcant diﬀerences between RA or PsA patients with IMT > 1 and those with IMT ≤ 1;
ESR: erythrocyte sedimentation rate; CRP: C reactive protein; IMT: intima-media thickness.
3.2. Serum ox-LDL Levels. Serum levels of ox-LDLs were
higher in patients with RA and PsA than in healthy subjects
(Figure 1). Whenpatients weredivided according to the IMT
value obtained by Echo-colour Doppler images, these levels
resulted higher in patients with IMT > 1 than in those with
IMT ≤ 1 and than in healthy subjects (PsA IMT > 1v e r s u s
PsA IMT ≤ 1, P = 0.0095; PsA IMT > 1 versus healthy
subjects, P = 0.049).
3.3. Serum NO and 3-Nitrotyrosine Levels. In contrast to ox-
LDLs, serum levels of NO were signiﬁcantly lower in patients
withRAandPsAthaninhealthysubjects(RAandPsAversus
healthy subjects P<0.0001, Figure 2), especially in patients
with IMT > 1. The diﬀerence between patients and healthy
subjects remained statistically signiﬁcant also when patients
where divided according to the IMT value (RA IMT > 1
versus healthy subjects, P = 0.0008; RA IMT ≤ 1, PsA IMT >
1a n dP s AI M T≤ 1 versus healthy subjects, P<0.0001).
To evaluate whether the signiﬁcant decreased levels
of NO in patients were due to a consumption of this
compound in proinﬂammatory conditions we evaluated the
modiﬁcation of tyrosine residues to 3-nitrotyrosine in serum
proteins. We observed that 3-nitrotyrosine levels were higher
in patients than in healthy subjects (PsA versus healthy
subjects P = 0.03, Figure 3).
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Figure 1: Oxidized low-density lipoprotein (ox-LDL) concentrations
in serum samples. Box plot graphs showing ox-LDL concentrations
in serum samples from the 24 patients with rheumatoid arthritis
(RA) and 25 with psoriatic arthritis (PsA), divided or not according
to IMT values obtained by Echo-colour Doppler images and from
the 13 healthy subjects. ∗P = 0.049; †P = 0.0095.
3.4. Serum Vitamin Levels. Patients with PsA showed sig-
niﬁcantly higher levels of vitamin A in serum compared to
patients with RA and to healthy subjects (PsA versus RA, P =
0.0004; PsAversushealthysubjects,P = 0.0014,Figure 4(a)).
When these patients were divided according to IMT values,4 Mediators of Inﬂammation
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Figure 2: Nitric oxide (NO) concentrations in serum samples.B o x
plot graphs showing NO concentrations in serum samples from the
24 patients with rheumatoid arthritis (RA) and 25 with psoriatic
arthritis (PsA), divided or not according to IMT values obtained
by Echo-colour Doppler images and from the 13 healthy subjects.
∗‡§# P<0.0001; †P = 0.0008.
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Figure 3: 3-Nitrotyrosine concentrations in serum samples. Box plot
graphs showing 3-nitrotyrosine concentrations in serum samples
from the 24 patients with rheumatoid arthritis (RA) and the 25
patients with psoriatic arthritis (PsA), divided or not according to
IMT values obtained by Echo-colour Doppler images and from the
13 healthy subjects. ∗P = 0.03.
vitamin A levels resulted higher only in patients with IMT
≤ 1 in comparison to healthy subjects (P = 0.0014). In PsA
patients with IMT > 1, levels of vitamin A were similar to
those found in RA patients and in healthy subjects.
Patients with RA and PsA showed signiﬁcantly lower
levels of β-carotene compared to healthy subjects (RA versus
healthysubjects,P = 0.0021;PsAversushealthysubjects,P =
0.0008, Figure 4(b)). The diﬀerence between patients and
healthy subjects remained statistically signiﬁcant also when
patients where divided according to the IMT value, except
for RA patients with IMT > 1( R AI M T≤ 1 versus healthy
subjects, P = 0.0065; PsA IMT > 1 versus healthy subjects,
P = 0.018;PsAIMT ≤1versushealthysubjects,P = 0.0006).
No signiﬁcant diﬀerences in vitamin E serum levels were
observed between patients and healthy subjects or between
patients divided according to IMT values (Figure 4(c)).
3.5. Analysis of Correlations. Analysis of possible correlations
among clinical and serological variables showed the presence
of a positive correlation between ox-LDL serum and total
cholesterol levels in patients with RA (r = 0.52, P = 0.028),
andanegativecorrelationbetweenNOserumlevelsandIMT
values in patients with RA and PsA (r =− 0.3, P = 0.033,
Figure 5(a)). In patients with RA, a negative correlation
was observed between β-carotene levels and the duration of
disease (r =− 0.62, P = 0.028, Figure 5(b)).
4. Discussion
The results of the present study indicate that ox-LDLs
and NO may have a role as biomarkers of accelerated
atherosclerosis in patients with RA and PsA. Patients with
RAhaveanelevatedriskofdeveloping cardiovasculardisease
and the major underlying cause is an accelerated progression
of atherosclerosis. Such a phenomenon is likely due to
the fact that RA patients are exposed to chronic systemic
inﬂammation, which is known to be a major driver of
atherosclerosis. It was demonstrated that circulating markers
of systemic inﬂammation confer a signiﬁcantly higher risk
of cardiovascular death among patients with RA even after
controlling for traditional cardiovascular risk factors [26].
Unlike RA, only recently some studies have provided a basis
for the potential association between PsA and atherosclerotic
disease [7, 21, 27]. Risk factors for atherosclerosis in
patients with RA and PsA include “traditional” risk factors
(mainly the Framingham risk factors), as well as disease-
related factors including disease duration, therapy, and
inﬂammatory biomarkers. Most atherosclerotic risk factors
accelerate disease progression by augmenting the production
of reactive oxygen species (ROS). As a consequence of ROS
overproduction, the cells enter a state of “oxidative stress”
in which protein function in the cell is chemically modiﬁed.
ROS formed during normal aerobic metabolism can also
react with proteins, cholesterol, and polyunsaturated fatty
acids of LDL leading to the development of oxidatively
modiﬁed LDL [28]. Oxidative modiﬁcation of LDL in the
vascular endothelium is considered to be a key factor in the
development of early atherosclerosis [29]. Our study here
demonstrating higher ox-LDL serum levels in patients with
RA and PsA than in healthy subjects conﬁrms and extends
previous studies reporting that ox-LDLs are raised in RA
[30]. When we analyzed results on ox-LDL according to the
presence or not of subclinical atherosclerosis, we observed
a positive association of ox-LDL levels with intima-media
thickness. In particular, PsA patients with atherosclerotic
disease have ox-LDL levels signiﬁcantly higher than patients
without it. We can conclude that ox-LDLs, which have
important proinﬂammatory properties, may play a role not
only in RA and PsA per se but also in the chronic inﬂam-
matory condition of atherosclerosis. The association of
atherosclerosiswithelevatedox-LDLssupportthehypothesis
that chronic systemic autoimmune inﬂammatory process is
probably a driving force for premature atherosclerosis.
The results of the present study also showed that NO, in
contrast to ox-LDLs, is decreased in sera from patients withMediators of Inﬂammation 5
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Figure 4: Vitamin concentrations in serum samples. (a) Box plot graphs showing vitamin A concentrations in serum samples from the 24
patients with rheumatoid arthritis (RA) and 25 with psoriatic arthritis (PsA), divided or not according to IMT values obtained by Echo-
colour Doppler images and from the 13 healthy subjects. ∗P = 0.0004;
†‡P = 0.0014. (b) β-carotene concentrations in sera. Box plot graphs
showing β-carotene concentrations in serum samples from the 24 patients with rheumatoid arthritis (RA) and 25 with psoriatic arthritis
(PsA), divided or not according to IMT values obtained by Echo-colour Doppler images and from the 13 healthy subjects. ∗P = 0.0021;
§P = 0.0008;
†P = 0.006; #P = 0.018;
‡P = 0.0006.(c)VitaminEconcentrationsinsera.BoxplotgraphsshowingvitaminEconcentrations
in serum samples from the 24 patients with rheumatoid arthritis (RA) and 25 with psoriatic arthritis (PsA), divided or not according to IMT
values obtained by Echo-colour Doppler images and from the 13 healthy subjects.
RA and PsA, especially in those with subclinical atheroscle-
rosis. Levels of NO in patients resulted also negatively cor-
related to IMT values. Serum NO levels measured by ELISA
are mostly derived by iNOS induction and it is well known
that during inﬂammation, the amount of NO produced
by iNOS is increased. Previous studies reported increased
endogenous NO synthesis in RA, where it contributes to
T-cell dysfunction [31, 32]. Furthermore, serum levels of
nitrates, nitrites, and NOx (nitrites + nitrates) were found
tobesigniﬁcantlyreducedfollowinganti-TNF-alphatherapy
in RA patients [33]. The apparent contradictory ﬁndings
of our study with these previous results may be explained
as a consequence of NO consumption in patient sera after
reaction of NO with active substances such as superoxides
and consequent formation of peroxynitrites and nitrated
proteins. To evaluate this possibility we have analyzed levels
of 3-nitrotyrosine in protein serum samples. The presence of
higher3-nitrotyrosineserumlevelsinpatientsincomparison
to healthy subjects suggests that NO reduction in patient
sera may be in part due to its consumption. The small size
of our population samples and the possibility that other
mechanisms are involved in NO reduction may explain the
lack of statistical signiﬁcant diﬀerences in 3-nitrotyrosine
serum levels between patients with RA and healthy subjects
and the lack of correlation of these levels with IMT values.
Overall, our results on ox-LDLs and NO as biomark-
ers of cardiovascular risk in patients with RA and PsA
strengthen our previous results [17] and are in line with
ﬁndings indicating that ox-LDLs impair NO signalling and
endothelial function, thus contributing to the pathogenesis
of atherosclerosis [34].
In the organism, damage by ROS is counteracted with
natural antioxidants and nutritional antioxidants from diet
(i.e., vitamins E, C, carotenoids) [35]. Dietary antioxidants
are eﬃcient scavengers of free radicals which protect LDL
against oxidation and thus reduce the oxidative damage of
tissues [36]. Many factors other than dietary intake such as
geneticdiﬀerencesinabsorptionorhomeostaticmechanisms
and environmental exposures may inﬂuence between-person6 Mediators of Inﬂammation
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Figure 5: Correlations between clinical and serological variables. (a) Negative correlation between nitric oxide (NO) levels and intima-media
thickness (IMT) values in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients. R =− 0.3, P = 0.033. (b) Negative correlation
between β-carotene levels and the onset of the disease (evaluated in terms of year in which the disease was diagnosed) in RA patients.
R =− 0.62, P = 0.028.
variations in plasma antioxidant levels and oxidative stress
[37].
It is known that antioxidants may protect against
development of rheumatoid diseases by combating oxidative
stress [38]. Even though an inverse relationship between
systemicinﬂammationandantioxidant bloodlevelshasbeen
reported, relatively little is known about the inﬂuence of
antioxidant intake on initiation of these diseases in humans
[15,38].Inparticular,alackofinformationexistsontherela-
tionship between antioxidants and accelerated atheroscle-
rosis in patients with autoimmune rheumatic diseases. A
question our ﬁndings help to explain is whether serum levels
of vitamins, the natural antioxidants, are associated with
the presence or unpresence of atherosclerotic disease in RA
and PsA patients. Since the fat-soluble vitamins A, E, and
β-carotene are essential in the regulation of autoimmune
processes, the aim of the present study was to assess these
vitamins in patients with RA and PsA and to ﬁnd possible
correlations between vitamin levels and various clinical
parameters, in particular the presence or not of endothelial
dysfunction. Of note, we found that in patients with PsA,
vitamin A levels were signiﬁcantly higher only in subjects
with IMT ≤ 1. This result let us to hypothesize a possible
protective eﬀect of vitamin A on the cardiovascular system
in these patients. Clearly, this interesting possibility awaits
conﬁrmation in a larger number of patients. Considering
β-carotene, we observed that its levels were signiﬁcantly
lower in patients with RA and PsA than in healthy subjects
but they did not diﬀer in accordance to the presence of
subclinical atherosclerosis. Our results conﬁrm previous
ﬁndings demonstrating that plasma levels of carotenoid
were signiﬁcantly lower in RA compared with non RA
subjects and these diﬀerences remained after adjustment
with potential confounders such as smoking, that is reported
to aﬀect the serum concentrations of antioxidants [39].
The same authors suggested that the reduced antioxidant
concentrations found among participants with RA depend
on increased metabolism of antioxidants. In line with these
previousﬁndings,ourstudydidnotdisclose anyassociations
betweenantioxidantlevelsandpotentialconfoundersamong
the clinical and serological variables of patients. The lower
concentrations of β-carotene in patients in comparison with
healthy subjects and mainly the inverse correlation we found
between β-carotene content and the duration of RA suggest
an association of β-carotene levels with autoimmune disease
and not with intima-media thickness values. This result
further supports the occurrence of a redox imbalance in
this type of pathologies and could be connected to the
higher levels of ox-LDLs found in these patients. To sustain
our hypothesis, a recent report demonstrated that plasma
concentrations of β-carotene signiﬁcantly contribute to
determine the occurrence of oxidative modiﬁcation of LDL
in vivo [29]. In that report, the authors also demonstrated
that vitamin E does not inﬂuence the occurrence of ox-
LDLs. In agreement with this ﬁnding, in the present study,
we demonstrated unchanged vitamin E levels in the plasma
of patients in comparison to healthy subjects.
The limitations of this study are mainly related to its
small size, cross-sectional design, and characteristics that
prevent us from determining statistical signiﬁcances in
some cases and from inferring any causal link between the
associations reported here.
5. Conclusion
In conclusion, our study, although not establishing a
causal link between ox-LDL or NO levels and accelerated
atherosclerosis, suggests that these molecules may be oper-
ational as markers of atherosclerotic disease in patients with
RA and PsA. The detection of circulating ox-LDL and NOMediators of Inﬂammation 7
levels in these patients might be an adjunct to imaging
procedures as prognostic markers for the development of
atherosclerotic disease and could be useful to the clinical
management of patients. Our results also indicate that vita-
mins are associated only to the presence of the autoimmune
disorders.
Further studies are necessary to investigate the role of
vitamins in rheumatic diseases per se or in association with
cardiovascular disease and to assign to these antioxidants
moleculesaputativeroleasbiomarkersofcardiovascularrisk
in these patients.
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